Bristol-Myers Squibb's $74B deal for Celgene criticized, called risky By: New York Business Journal via Business Journals March 04, 2019 at 13:24 PM EST At least one shareholder said the $74 billion deal is "poorly conceived and ill-advised." Read More >>
